Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
FAQ
- What is Aquestive Therapeutics, Inc.'s D&A?
- Aquestive Therapeutics, Inc. (AQST) reported D&A of $136K in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s D&A changed year-over-year?
- Aquestive Therapeutics, Inc.'s D&A decreased by 2.9% year-over-year, from $140K to $136K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s D&A has grown at a -34.4% compound annual growth rate (CAGR), from $2.96M to $548K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Aquestive Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude